The congress is set to emphasize the expanding role of artificial intelligence in both diagnostics and therapeutics, showcasing pioneering methodologies designed to dissect tumor biology with unprecedented resolution. For instance, recent advances presented at the meeting will delve into the integration of spatial multi-omic mapping technologies in breast cancer research, shedding light on the mechanisms that govern circulating tumor DNA (ctDNA) release. This approach combines genomics, transcriptomics, and proteomics within the native tumor microenvironment, providing a holistic view essential to understanding the progression from early-stage lesions to invasive disease phenotypes.

Central to the congress discourse is the nuanced understanding of immune surveillance dynamics during oncogenesis. New data illuminating T cell behavioral patterns reveal critical modulations occurring well before overt malignancies manifest. By decoding these immune landscape changes at pre-cancerous stages, researchers aim to identify interception points where therapeutic intervention could effectively halt progression, marking a paradigm shift from reactive treatments to proactive cancer prevention.

Artificial intelligence’s role extends also to the development of computational models capable of early cachexia detection in patients with brain tumors. Cachexia, a multifactorial syndrome characterized by severe weight loss and muscle wasting, significantly impairs treatment outcomes. The introduction of AI-powered algorithms that analyze patient-specific data offers a promising route to early identification and management of cachexia, potentially improving quality of life and survival metrics in this vulnerable population.

Adding further complexity to the AI narrative is the concept of digital tumor twins—virtual replicas of an individual’s tumor constructed through integrative data modeling. These digital constructs serve as personalized experimental platforms, enabling simulation of therapeutic responses for cancers of unknown primary origin (CUP). Such innovations herald a new age of precision oncology, where treatments can be tailored with higher specificity and predictive accuracy, substantially augmenting clinical decision-making.

From a genomic perspective, the conference will highlight compelling evidence from clinical trials demonstrating that tumors harboring low levels of genomic alterations often exhibit exceptional responses to targeted therapies. This counterintuitive finding challenges prevailing assumptions that high tumor mutational burden correlates uniformly with treatment sensitivity, instead suggesting a more nuanced interplay between genomic architecture and therapeutic efficacy.

Within the program, a keynote lecture by renowned genomicist Núria López-Bigas will explicate the mutational processes underpinning cancer development. Her discourse promises to elucidate how endogenous and exogenous mutagenic forces sculpt the cancer genome, thereby influencing oncogenic trajectories and informing strategies for early detection and intervention.

Beyond the molecular and computational advances, the congress will also focus on emerging biological themes such as cellular senescence and its dualistic role in tumor suppression and promotion, the influence of aging on cancer susceptibility, and the burgeoning field of cancer metabolism. These topics underscore the intricate, interconnected systems biology at play in oncogenesis, advocating for multidimensional research approaches.

A further thrust at MAP 2025 is the exploration of the microbiome’s impact on tumorigenesis and treatment response. Recent studies suggest that the composition and functional state of microbial communities within patients may modulate immune response and influence drug metabolism, thus representing a fertile area for therapeutic innovation and biomarker development.

The organizers emphasize that this congress will be an exclusively onsite experience, promoting immersive scientific exchange without virtual attendance options. This decision underscores the value placed on face-to-face dialogue in fostering collaborative networks that accelerate translational research breakthroughs.

Complementing the scientific agenda, press accreditation is meticulously managed to ensure accurate dissemination of conference outputs, underscoring the event’s commitment to transparency and engagement with the wider medical community. Accredited journalists will gain privileged access to unveil the nuanced developments set to shape the future of precision oncology.

MAP 2025 stands as a testament to the vital collaboration among leading institutions, including Cancer Research UK, Unicancer, and the European Society for Medical Oncology (ESMO). This synergy exemplifies the global commitment to eradicating cancer through research that spans molecular insights to clinical implementation.

As technology converges with biology, MAP 2025 promises to chart new territories in cancer research, offering hope for earlier diagnosis, more effective prevention strategies, and personalized therapies that reflect the unique molecular signatures of each patient’s disease. The congress underscores that the future of oncology lies at the nexus of integrative science, multidisciplinary expertise, and cutting-edge innovation.

Subject of Research: Precision Oncology, Cancer Genomics, Artificial Intelligence in Cancer Diagnostics and Therapy

Article Title: Pioneering Precision Oncology: Insights from MAP 2025 on AI Integration, Genomics, and Tumor Biology

News Publication Date: August 27, 2025

Web References:

• https://www.esmo.org/meeting-calendar/molecular-analysis-for-precision-oncology-congress-2025
• https://cslide.ctimeetingtech.com/map2025/attendee/confcal/session/calendar/2025-09-15

Keywords: Oncology, Cancer Genomics, Cancer Screening, Oncogenes, Cancer Proliferation Genes, Molecular Oncology, Artificial Intelligence, Tumor Microenvironment, Cancer Metabolism, Cellular Senescence, Cancer Immunotherapy

Dr. Poschmann’s scientific journey is as unorthodox as it is inspiring. Trained originally as a nurse, he transitioned into systems biology, a shift fueled by a passion for uncovering the stories embedded within biological data. His early fascination with genome-wide discovery, particularly in model organisms like yeast, sparked a commitment to let data guide hypothesis generation rather than constraining research within pre-set questions. This mindset has proven transformative, enabling his team to develop novel signatures of immune function that capture patient-specific trajectories through health and illness.

Central to Poschmann’s research is the concept of the circulating immune system as a living archive of past immunological events. Blood serves not merely as a diagnostic medium but as a dynamic window into the layered histories of exposure, infection, and genetic predispositions that collectively shape immune competence. By applying multi-omics profiling — integrating genomic sequences, RNA expression profiles, and protein quantifications — his lab constructs highly detailed immune circuitry maps. This approach facilitates unprecedented resolution in defining immune states, immune memory, and their fluctuations across diverse populations.

These metabolic and molecular blueprints hold transformative potential for addressing pressing clinical challenges. For example, differing immune baselines could illuminate why viral infections like SARS-CoV-2 manifest with such heterogeneous outcomes among patients. By capturing a patient’s immunological signature prior to infection or treatment, Dr. Poschmann’s team aims to predict disease severity, response to vaccines, or even likelihood of developing neuropsychiatric sequelae. This paradigm shift from reactive to predictive immunology posits a future where personalized immune profiling guides tailored interventions and proactive health strategies.

Achieving these goals requires not only biological insight but also sophisticated computational frameworks. Frustrated early in his career by the bottlenecks posed by limited bioinformatics support, Dr. Poschmann acquired programming skills independently. This technical self-reliance catalyzed a new approach to research wherein iterative data analysis, machine learning models, and systems-level integration occur fluidly within the lab. By embracing computational fluency, his group models immune complexity with high dimensionality and temporal depth — essential for decoding the stochastic yet patterned nature of immune regulation.

An emerging theme in Poschmann’s work is the profound impact of pre-existing immune conditions shaped by an individual’s life history, environment, and genetics. These foundational immune landscapes help explain individual variability in susceptibility and resilience to disease. Understanding these intrinsic immune “set points” and their molecular underpinnings represents a crucial step towards deploying immune monitoring as a routine clinical tool. Such insights may eventually inform vaccine formulation strategies optimized for subpopulations or identify early biomarkers predictive of psychiatric disorders linked to immune dysfunction.

Beyond the laboratory bench, Dr. Poschmann actively advocates for systemic improvements in research infrastructure, particularly emphasizing the need for stable career pathways for postdoctoral researchers and technical staff. He asserts that scientific advances depend heavily on continuity and collaboration, elements threatened by precarious employment conditions prevalent in academic research across Europe. Poschmann’s call to action highlights the importance of investing in the entire scientific ecosystem to sustain innovation and knowledge transfer.

At the core of his leadership is a holistic, inclusive philosophy that values originality and mindset over traditional metrics like grades. Drawing on his nursing background, he fosters a lab culture rooted in compassion, mentorship, and interdisciplinary collaboration. This ethos not only nurtures creativity but also attracts talent capable of thinking differently about complex biological problems, which is essential in navigating the multi-faceted challenges of systems immunology.

Outside the intellectual rigor of research, Poschmann finds balance in the Atlantic waves off the French coast. Surfing has become both a metaphor and practical outlet for patience, resilience, and timing — qualities mirrored in the patient, deliberate process of scientific discovery. The capricious rhythm of the ocean aligns with the uncertainty scientists embrace, where persistence eventually meets breakthrough.

Dr. Poschmann’s work exemplifies the increasingly blurred boundaries between biology, computation, and medicine. His ambition is not merely to deepen biological insights but to translate them meaningfully into clinical care. By harnessing multi-omics data and system-level analyses, he envisions a healthcare future where immune profiling informs personalized therapies, preventive measures, and real-time disease monitoring.

The implications of this research ripple far beyond immunology, touching psychiatric medicine, infectious disease management, and public health policy. The ability to quantify and interpret immune memory at scale may revolutionize how society approaches vaccination, treatment customization, and early intervention for a myriad of diseases influenced by immune dysfunction.

As the multi-omics revolution continues, several critical questions demand attention. How can complex, high-dimensional immune data be distilled into actionable clinical metrics accessible at the point of care? What infrastructural and computational frameworks must be developed to support widespread use of personalized immune profiles? And fundamentally, what societal investment and scientific collaboration will break down barriers preventing the realization of a prevention-first, precision health model?

Dr. Jeremie Poschmann’s journey and research represent a compelling microcosm of modern biomedicine’s evolution towards data-driven, integrative approaches. His pioneering multi-omic profiling of the circulating immune system not only advances scientific understanding but also lays the groundwork for a transformative impact on healthcare delivery, fostering a future where personalized medicine is the norm rather than the exception.

Subject of Research: People

Article Title: Jeremie Poschmann: Data-driven discovery in human diseases through multi-omics profiling of the circulating immune system

News Publication Date: 22-Apr-2025

Web References:
https://doi.org/10.61373/gp025k.0023
https://genomicpress.kglmeridian.com/

Image Credits: Jeremie Poschmann, PhD

Keywords: multi-omics, circulating immune system, systems biology, immunology, genomics, transcriptomics, proteomics, personalized medicine, immune profiling, data-driven discovery, SARS-CoV-2, vaccine response, psychiatric disorders